Ophthotech Corporation to Host R&D Investor Day on December 3, 2015

– Webcast to Begin at 8:30 a.m. Eastern Time –

NEW YORK–(BUSINESS WIRE)–Ophthotech Corporation (NASDAQ:OPHT) announced today that the Company
will host a live webcast in conjunction with its Research and
Development (R&D) Investor Day on Thursday, December 3, 2015, beginning
at 8:30 a.m. ET. Ophthotech’s management will provide an overview of the
Company’s Fovista^® (pegpleranib) programs in the current
treatment paradigm of wet age-related macular degeneration. The Company
will host a panel discussion with a leading group of retina specialists.

The live and archived webcast can be accessed through the Investor
section of the Company’s website at www.ophthotech.com.
Please connect to Ophthotech’s website several minutes prior to the
start of the presentation to ensure adequate time for any software
download that may be necessary. A replay will remain available on the
Company’s website for 14 days following the presentation.

About Ophthotech Corporation

Ophthotech is a biopharmaceutical company specializing in the
development of novel therapeutics to treat back of the eye diseases,
with a focus on developing innovative therapies for age-related macular
degeneration (AMD). Ophthotech’s most advanced product candidate, Fovista^®
anti-PDGF therapy, is in Phase 3 clinical trials for use in combination
with anti-VEGF therapy that represents the current standard of care for
the treatment of wet AMD. Ophthotech’s second product candidate, Zimura^®,
an inhibitor of complement factor C5, is being developed for the
treatment of geographic atrophy, a form of dry AMD. For more
information, please visit www.ophthotech.com.

Forward-looking Statements

Any statements in this press release about Ophthotech’s future
expectations, plans and prospects constitute forward-looking statements
for purposes of the safe harbor provisions under the Private Securities
Litigation Reform Act of 1995. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors. Any forward-looking statements represent
Ophthotech’s views only as of the date of this press release. Ophthotech
anticipates that subsequent events and developments will cause its views
to change. While Ophthotech may elect to update these forward-looking
statements at some point in the future, Ophthotech specifically
disclaims any obligation to do so.

OPHT-G

Contacts

Investors
Kathy Galante
Ophthotech Corporation
Vice
President, Investor Relations and Corporate Communications
212-845-8231
kathy.galante@ophthotech.com
or
Media
Jennifer
Devine
SmithSolve LLC on behalf of Ophthotech Corporation
973-442-1555
ext. 102
jennifer.devine@smithsolve.com